Výsledky vyhledávání - "Veronica, Tebbs"

Data from An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

Autor: Mirjana Urosevic, Tze-Chiang Meng, Ruth Clark, Stephanie Moosbauer, Katharina C. Kaehler, Jeannine Skalsky, Veronica Tebbs, Dirk Schadendorf, Jean-Jacques Grob, Juergen C. Becker, Axel Hauschild, Reinhard Dummer

Purpose: A topical Toll-like receptor 7 (TLR7) agonist induces regression of cutaneous melanocytic neoplasms. We explored antitumor activity of a systemically administered TLR7 agonist, 852A, in patients with metastatic melanoma.Experimental Design:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ca096efff96a7a1ef33a83ff492d44
https://doi.org/10.1158/1078-0432.c.6518293

Zobrazit plný text záznamu

Supplementary Table S1 from An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

Supplementary Table S1 from An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdfc78e095ae18697c3ca713e007eac3
https://doi.org/10.1158/1078-0432.22441153.v1

Zobrazit plný text záznamu

A multicentre, randomised, parallel‐group, double‐blind, vehicle‐controlled and open‐label, active‐controlled study (versus amorolfine 5%), to evaluate the efficacy and safety of terbinafine 10% nail lacquer in the treatment of onychomycosis

Autor: Veronica Tebbs, Ulrike Blume-Peytavi, Cristina Carreño, Meritxell Falqués, Maria Luisa Tamarit, Jordi Galván, Antonella Tosti

Background Onychomycosis is a difficult-to-treat fungal nail infection whose treatment can involve systemic or topical antifungal approaches. Objectives To assess the efficacy and safety of terbinafine 10% nail lacquer in distal lateral subungual ony

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a77292ff3726a94b27d6aa41dc1d448
https://doi.org/10.1111/myc.13392

Zobrazit plný text záznamu

An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma

Autor: Jean-Jacques Grob, Ruth Clark, Stephanie Moosbauer, Axel Hauschild, Jeannine Skalsky, Tze-Chiang Meng, Katharina C. Kaehler, Dirk Schadendorf, Mirjana Urosevic, Veronica Tebbs, Reinhard Dummer, Juergen C. Becker

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51017d75f691456a5d66fec22836d868

Zobrazit plný text záznamu

Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe

Autor: Harald, Gollnick, Carlos Guillén, Barona, Ronald G J, Frank, Thomas, Ruzicka, Mosaad, Megahed, Veronica, Tebbs, Mary, Owens, Patti, Stampone

Publikováno v: European journal of dermatology : EJD. 15(5)

Imiquimod is an immune response modifier that acts through Toll-like receptor 7 to induce innate and cell-mediated immune responses. This ongoing phase III, open-label study conducted in Europe is evaluating the long-term (5 year) clinical efficacy a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::08e3dbd5a4dd22d32fcfd815ed27fe43
https://pubmed.ncbi.nlm.nih.gov/16172048

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání